Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation

Xenotransplantation

Volumn 21, Issue 4, 2014, Pages 367-375

  Ramackers, Wolf ^a   Friedrich, Lars ^a   Klose, Johannes ^a   Vondran, Florian ^a   Bergmann, Sabine ^a   Schüttler, Wolfgang ^a   Johanning, Kai ^a   Werwitzke, Sonja ^a   Trummer, Arne ^a   Bröcker, Verena ^a   Klempnauer, Jürgen ^a   Winkler, Michael ^a   Tiede, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

coagulation; ex vivo perfusion; xenokidney transplantation

Indexed keywords

ANTITHROMBIN; D DIMER; DROTRECOGIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; PADGEM PROTEIN; PLASMINOGEN; RECOMBINANT HUMAN ANTITHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; PROTEIN C; RECOMBINANT PROTEIN;

ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING PARAMETERS; DRUG EFFECT; ENDOTHELIUM CELL; EX VIVO STUDY; HEMOSTASIS; HUMAN; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; THROMBOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR RESISTANCE; XENOGENIC ACTIVATION OF HEMOSTASIS; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; BLOOD; BLOOD CLOTTING; DOSE RESPONSE; DRUG EFFECTS; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PIG; PROCEDURES; THROMBOTIC MICROANGIOPATHIES; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTITHROMBIN PROTEINS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; HEMOSTASIS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MODELS, BIOLOGICAL; PERFUSION; PLATELET ACTIVATION; PROTEIN C; RECOMBINANT PROTEINS; SUS SCROFA; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR RESISTANCE;

EID: 84905696499     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12104     Document Type: Article

References (28)

1. Cooper DK, Hara H, Ezzelarab M, et al. The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation. J Biomed Res 2013; 27: 249-253.
2. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089-1092.
3. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
4. Ierino FL, Kozlowski T, Siegel JB, et al. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 1998; 66: 1439-1450.
5. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
6. Hecker JM, Lorenz R, Appiah R, et al. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation 2002; 73: 688-694.
7. Cozzi E, Simioni P, Boldrin M, et al. Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation. Am J Transplant 2004; 4: 335-345.
8. Lin CC, Cooper DK, Dorling A,. Coagulation dysregulation as a barrier to xenotransplantation in the primate. Transpl Immunol 2009; 21: 75-80.
9. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
10. Ramackers W, Friedrich L, Tiede A, et al. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 2008; 15: 46-55.
11. Petersen B, Ramackers W, Tiede A, et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16: 486-495.
12. Dickneite G,. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24: 61-69.
13. Ezzelarab M, Cortese-Hassett A, Cooper DK, Yazer MH,. Extended coagulation profiles of healthy baboons and of baboons rejecting GT-KO pig heart grafts. Xenotransplantation 2006; 13: 522-528.
14. Petersen B, Ramackers W, Lucas-Hahn A, et al. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation 2011; 18: 355-368.
15. Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
16. Lavrentieva A, Kontakiotis T, Bitzani M, et al. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost 2008; 100: 286-290.
17. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.
18. Sun HM, Hong LZ, Shen XK, et al. Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. Chin Med J (Engl) 2009; 122: 2466-2471.
19. Wiedermann CJ, Kaneider NC,. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006; 17: 521-526.
20. Zarbock A, Ley K, McEver RP, Hidalgo A,. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011; 118: 6743-6751.
21. Martin J, Collot-Teixeira S, McGregor L, McGregor JL,. The dialogue between endothelial cells and monocytes/macrophages in vascular syndromes. Curr Pharm Des 2007; 13: 1751-1759.
22. Binder FP, Ernst B,. E- and P-selectin: differences, similarities and implications for the design of P-selectin antagonists. Chimia (Aarau) 2011; 65: 210-213.
23. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res 2009; 83: 388-396.
24. Chappell D, Hofmann-Kiefer K, Jacob M, et al. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol 2009; 104: 78-89.
25. Kappelmayer J, Nagy B Jr, Miszti-Blasius K, Hevessy Z, Setiadi H,. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42: 475-486.
26. Cowan PJ, Aminian A, Barlow H, et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2: 520-525.
27. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80: 1501-1510.
28. Tiede A, Tait RC, Shaffer DW, et al. Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 2008; 99: 616-622.